News: South Korea

2 August 2021

Regdanvimab Reduced The Risk of COVID-19-related Hospitalization or Death for Patients with Comorbidities

Regdanvimab (RegkironaTM) is recommended to treat confirmed COVID-19 in adult patients who do not require supplemental oxygen therapy and are at high risk of progressing to severe COVID-19. The recommended dosage of Regdanvimab is a single intravenous infusion of 40 mg/kg. Treatment should be initiated as soon as possible after…